Commenting on these management changes, Dr Keith McCullagh, Affitech's Chairman, said: "I am delighted to welcome Robert Burns and Alex Duncan to Affitech. They bring exceptional experience in structuring biotech alliances and the discovery and development of competitive human antibody medicines. I am confident that under their business and scientific leadership the recently listed Affitech will emerge as an exciting new international competitor in the rapidly growing pharmaceutical sector of human antibody medicines."
"I would also like to thank Dr Achim Kaufhold for his dedication and commitment to the success of Affitech over the last year and wish him every success as he returns to Switzerland to pursue other opportunities.
Dr Robert Burns, Affitech's new CEO, commented: "Alex and I are both excited to be joining the Affitech team at this transformational point. The Company has developed powerful antibody selection technology that has already shown success in generating potential human antibody drugs against previously challenging new disease targets. I think Affitech has a strong competitive advantage in the antibody field and I look forward to building the business into an internationally successful biopharmaceutical company."
The management changes announced today take place with immediate effect.
Affitech A/S is a human
|SOURCE Affitech AS|
Copyright©2009 PR Newswire.
All rights reserved